News
Find out all about our firm’s latest news and activities below. To learn more about any individual item, please contact us here.
News
Find out all about our firm’s latest news and activities below. To learn more about any individual item, please contact us here.
Introduction
On 15 December 2017, Hong Kong Exchange and Clearing Limited (“HKEX”) published the Consultation Conclusions on the New Board Concept Paper (the “New Board Consultation Conclusions”), proposing a “way forward” to expand the existing listing regime. Please click here for our previous news update outlining the summary of the proposals. In gist, the Consultation Conclusions proposes: (1) to allow pre-revenue issuers engaging in biotech products, processes or technologies (“Biotech Issuers”) and innovative and high growth issuers that have Weighted Voting Rights Structure (“WVR Structure”) to list on The Stock Exchange of Hong Kong Limited (“SEHK”); and (2) to create a new concessionary secondary listing route for innovative issuers that are primary listed on a qualifying exchange.
Through discussions with the Securities and Futures Commission (“SFC”) and stakeholders, HKEX has published on 23 February 2018 a Consultation Paper on a Listing Regime for Companies from Emerging and Innovative Sectors (the “Consultation Paper”), to follow up its proposals in the Consultation Conclusions. The Consultation Paper contains detailed proposals and introduces two new chapters and certain amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”). The proposals in the Consultation Paper closely follow the “way forward” contained in the Consultation Conclusions.
Among the updates, there are certain key new proposals worth paying attention to:
Listing of Pre-revenue Biotech Issuers
● Biotech Issuers must have developed at least one Core Product (i.e. a regulated product that forms the basis of a Biotech Issuer’s listing application under the Listing Rules) beyond the concept stage.
● Biotech Issuers must be able to show that it has been engaged with research and development of its Core Product(s) for a minimum of 12 months prior to listing.
● SEHK will recognise the US Food and Drug Administration, the China Food and Drug Administration and the European Medicines Agency as competent authorities for the purpose of assessing the Core Products of Biotech Issuers under the Listing Rules.
● Biotech Issuers must have previous meaningful third party investment from at least one sophisticated investor at least six months before the date of listing.
● Biotech Issuers listed under the new Biotech chapter will be restricted from effecting any transaction that will result in a fundamental change to its principal business without its prior consent. Further, any Biotech Issuers who fail to maintain sufficient operations or assets would be given a period of up to 12 months to re-comply with the relevant continuing obligations, failing which SEHK will cancel its listing.
Issuers with WVR Structure
● SEHK will require beneficiaries under a WVR Structure to collectively own a minimum of at least 10% and a maximum of not more 50% of the underlying economic interest in the applicant’s total issued share capital (e.g. dividend rights) at the time of the issuers’ initial listing. However, this will not be an ongoing requirement.
● Only individuals who are directors of the issuer at listing and remain as directors can be beneficiaries of a WVR Structure. The effect is that the WVR Structure would naturally fall away over time.
● The WVR Structure can only be attached to a specific class of shares, which must be unlisted.
● WVRs attached must confer to a beneficiary only enhanced voting power on resolutions tabled at the issuer’s general meetings. Beneficiaries of a WVR Structure would not be able to exercise their enhanced voting powers on matters such as to change the issuer’s constitutional documents, however framed.
Concessionary Route to Secondary Listing
● Applicants that have primary listing in the US or other major international exchanges must demonstrate, to the satisfaction of SEHK, how the combination of domestic laws, rules and regulations to which they are subject and their constitutional documents, are able to satisfy the Key Shareholder Protection Standards under section 1 of The Joint Policy Statement Regarding the Listing of Overseas Companies jointly issued by the SFC and SEHK in September 2013
● A Non-Greater China Issuer with a WVR structure or a Grandfathered Greater China Issuer with a WVR Structure who list in Hong Kong through the new concessionary secondary listing route, may not be required to comply with most new requirements applicable to issuers with a WVR Structure who list directly in Hong Kong.
Moreover, SEHK pointed out that what is considered “innovative” will change over time as technology, markets and industries develop and change. It is therefore important to note that the fact that a previous company has qualified for listing with a WVR structure does not necessarily mean that another applicant with a similar technology, innovation or business model will also qualify for listing with a WVR structure.
Conclusions
The quick publication of detailed proposals and draft amendments to the Listing Rules show HKEX’s commitments to reform the listing regime to offer more choices for emerging and innovative companies to list in Hong Kong. To show HKEX’s receptiveness to suggestions, the Consultation Paper further proposes that if the amendments related to WVR are implemented, HKEX will launch a separate consultation within three months of such implementation to explore on whether to allow corporate entities to become beneficiaries of a WVR Structure. In light of these encouraging developments, we all look forward to seeing Hong Kong continue to be an attractive venue for raising capital.
This newsletter is for information purposes only. Its content does not constitute legal advice, and should not be treated as such. Stevenson, Wong & Co. will not be liable to you in respect of any special, indirect or consequential loss or damage.
Please contact our Hank Lo or Rodney Teoh for any enquiries or further information.
Jessica Run 2018 was successfully held at Cyberport on 8 April 2018, organized by《JESSICA》and “JESSICA Foundation”. Stevenson, Wong & Co. fully supported this meaningful charity run event. We not only made a donation, but our litigation team including associate Kyle Lo, Evania Mok, Jensen Chang and trainee solicitor Calvin Huang also participated in the 3km Corporate Team Challenge.

From left to right: Mr. Calvin Huang (trainee solicitor); Mr. Jensen Chang (associate); Ms. Evania Mok (associate); Mr. Kyle Lo (associate).

From left to right: Ms. Evania Mok; Executive Vice Chairman of South China Media Ms. Jessica Ng; Mr. Calvin Huang; Mr. Kyle Lo and Mr. Jensen Chang.




About Jessica Run
“JESSICA Run” is a charity run event organized since 2007 by《JESSICA》and “JESSICA Foundation”. It aims to bring family members together through this charity run, as well as to raise funds for those in need of help. All funds raised were donated to “JESSICA Foundation”, “Women Helping Women Hong Kong” “Society for Abandoned Animals”, “Sowers Action” and “Make-A-Wish® Hong Kong”.
Please contact Ms. Heidi Chui for any inquiry or further information about this event.
Stevenson, Wong & Co. advised Grand Brilliance Group Holdings Limited (“Grand Brilliance”, Stock Code: 8372) as its Hong Kong legal advisers on its initial public offering (“IPO”) on GEM of Hong Kong Stock Exchange.
The IPO comprised an issue of a total of 168 million shares priced at HK$0.335 per share, raising gross proceeds of approximately HK$56.3 million.
Grand Brilliance is an established medical device distributor with over 19 years of experience in the medical device market in Hong Kong. Grand Brilliance’s customers include private and public hospitals, private clinics, non-profit organisations and universities in Hong Kong.
The SW team was led by corporate partners Hank Lo and Cornelia Chu and senior associate Terence Lau, supported by registered foreign lawyer Matthew Chan and paralegal David Leung.
The Sole Sponsor is Guotai Junan Capital Limited. The Sole Global Coordinator is Guotai Junan Securities (Hong Kong) Limited.

From left to right: Matthew Chan (registered foreign lawyer); Terence Lau (senior associate); Ms. Wong Bik Kwan Bikie (the chairman and CEO of Grand Brilliance); Hank Lo (partner)


(中文) 江苏省涉外律师培训正在南京大学进行,国际商会于2018年3年23至25日一连三天为江苏省精英青年律师提供国际商会国际仲裁培训,本所合伙人、诉讼及争议排解部门主管徐凯怡律师获邀担任国际商会讲师团成员,并担任小组导师。培训一连三天在南京东南大学中山院举办,近三十位精英青年律师参加。

在首日的培训,课程统筹、前香港法院法官、现任香港大学法律学院教授芮安牟教授 (Prof. Anselmo Reyes) 致欢迎词。芮安牟教授表示希望参加学员在经过这三天的培训,能让大家对国际仲裁有更深入了解。
培训课程由国际商会邀请的讲师授课,包括芮安牟教授、课程统筹、国际商会(北亚地区) 助理主任黄一文女士、本所合伙人徐凯怡律师、英国特许仲裁司学会东亚分会副主席方兆文先生、金茂律师事务所合伙人韩正律师、香港大律师陈星南先生、香港大律师梁希贤先生、汇仲律师事务所(上海)高级顾问刘京律师等。
为了让学员深入了解国际仲裁、国际商会在这三天培训中设有多个环节、包括主题演讲、小组讨论、模拟仲裁示范、大型研讨会及仲裁比赛。本所合伙人徐凯怡律师除了担任小组导师,带领一众学员从多角度分析国际仲裁的做法及解答学员对国际仲裁的疑问,并分享「从当事人角度看仲裁员的选择和任命」这课题。




国际仲裁培训课程的最后一天,学员分为四组,在导师包括徐凯怡律师、韩正律师、梁希贤大律师及陈星南大律师的领导下,进行了一场既刺激又紧张的仲裁比赛,各学员把连日来学习的知识演活在仲裁比赛上。胜出的团队更可获赠得由芮安牟教授撰写的作品《The Practice of International Commercial Arbitration》为奖品。

由左至右: 英国特许仲裁司学会东亚分会副主席方兆文先生、本所合伙人徐凯怡律师、国际商会(北亚地区) 助理主任黄一文女士、江苏省律协涉外业务委员会主任、国浩律师事务所合伙人陈发云律师、以及金茂律师事务所合伙人韩正律师
如欲查询是次活动,请联络本所徐凯怡律师。
(中文) 史蒂文生黄律师事务所合伙人徐凯怡律师及张源辉律师,联同公共关系部经理叶慧珍小姐于2018年3月22日到访锦天城南京分所参观交流,双方就诉讼及仲裁和资本巿场(上市及收购合并)等议题举行交流座谈会,并获多位南京分所同仁热切款待,包括南京分所主任倪同木律师、高级合伙人奚庆律师、何海军律师、张宇坤律师、王芳律师、王小晶律师、刘嘉豪资深律师、以及南京分所行政主管吴小红女士等。

交流会由锦天城高级合伙人张宇坤致欢迎词掀开序幕,奚庆律师也介绍了南京分所的专业领域。

本所合伙人、诉讼及争议排解部门主管徐凯怡律师在交流会上就「跨境诉讼与仲裁」发表演讲。徐律师利用不同的案例,深入浅出地向大家阐述跨境诉讼与仲裁的各种情况,并互相讨论。徐律师更向大家分享第三方资助仲裁的最新发展。


另外,合伙人张源辉律师也介绍了本所企业融资部门的团队及业务,也分享了本所在去年处理上市及收购合并的项目。


最后,南京分所主任倪同木律师肯定了这次交流会的成果,对本所的到访与分享表示感谢,期待未来两所有更多合作,并祝愿两所有更好的发展。


In July 2017, Mr. Ashley Alder, the Chief Executive officer of the Securities and Futures Commission (“SFC”) introduced a new approach to regulate licensed corporations, listed companies and companies that are applying to be listed on the Stock Exchange of Hong Kong. This new approach, often called the “front-loaded regulation”, aims to identify risks and minimise harm to the investing public from market misconduct and irregularities. It places a strong emphasis on “earlier, more targeted intervention”.
Conventional approach
There are three main arms of the SFC’s regulatory work. The first arm is education. The SFC would issue reports, circulars and guidelines periodically to provide regulatory guidance for the investing public, companies (listed and non-listed), and licensees. The second arm is the Intermediaries Division, which carries out licensing and supervisory functions. Regarding its supervisory role, it acts as a ‘good cop’ to perform regular inspections on regulated licensees with a view to protect the investing public. When material irregularities are found during inspections, the Intermediaries Division would refer the case to the Enforcement Division. The final arm is the Enforcement Division, which takes criminal, civil and disciplinary actions against offenders following investigations into the alleged irregularities or market misconduct.
Issues with the conventional approach
Traditionally, the SFC has primarily relied on the Enforcement Division to carry out its regulatory enforcement functions. On top of that, enforcement powers may only be exercised through a Court or the Market Misconduct Tribunal (“MMT”). This approach can be very time-consuming because all sanctions and remedies were dependent on the approval from the Court or MMT. Once the Intermediaries Division has referred a case to the Enforcement Division, the Enforcement Division would carry out further in-depth investigation into the alleged irregularity before commencing proceedings. The ensuing proceedings in the Court or MMT would also take a considerable amount of time.
Moreover, the transition of cases from the Intermediaries Division to the Enforcement Division may not always be smooth, due to the difference in their investigation approach and evidence gathering methodology causing unnecessary delay that may risk losing the opportunity for timely fact-finding. As a result, the irregularities or market misconducts might usually be needlessly prolonged.
New approach – “early intervention”
Under the new approach, the SFC will take pre-emptive measures to tackle market irregularities and “interact directly with the market at an early stage”.
In terms of administrative measures, the Intermediaries Division will now issue more thematic guidance to licensees and companies on how the SFC intends to deal with specific issues under the Securities and Futures Ordinance (“SFO”) and the Securities and Futures (Stock Market Listing) Rules (“SMLR”). Such thematic guidance will require licensees and companies to conduct internal control reviews regularly to check for irregularities. The active review will be done by the company/licensee so that irregularities can be identified and dealt with immediately.
The SFC may also issue a restriction notice pursuant to ss. 204 and 205 of the SFO. This gives the SFC powers to prohibit the targeted company or licensee from carrying out specific regulated activities that would create irregularities. The issue of restriction notice aims to preserve the assets of the licensee and its clients, and protect the interest of those clients and the investing public. While the SFC has been issuing restriction notices long before the adoption of the new approach, we can expect the SFC to exercise such powers more readily in the future in light of the new approach.
Regarding the disciplinary actions and proceedings brought by the Enforcement Division, the SFC will now be able to exercise enforcement powers without prior approval from the Court/MMT. Under the SMLR, the SFC could suspend a listed company without the need to seek Court approval. The SFC has indicated that it would use such power of suspension as an “exceptional early protective action” during an investigation pending further investigation or legal action.
Furthermore, the SFC will now give credit to the people and/or licensees who are willing to cooperate with the SFC in their investigations. Forms of cooperation may include, inter alia, voluntarily and promptly reporting any breaches or failings to the SFC, acceptance of liability, and taking rectification measures. In both disciplinary matters and Court/MMT proceedings, the SFC may reduce the sanctions imposed if the person/licensee is cooperative. In particular, the SFC has divided its disciplinary process into three stages, with sanction reduction up to 30%, 20% and 10% respectively. These changes to the SFC’s cooperation policy may give rise to more constructive solutions in resolving irregularities, while keeping the daily operations of the company intact. These benefits should help to provide more incentive for people and licensees to cooperate with the SFC.
Overall, the Intermediaries Division will be more proactive in exercising its supervisory powers, meanwhile, the Enforcement Division will only focus on the most serious issues, such as fraud and corporate misfeasance, which would have serious ramifications to the integrity of the capital markets of Hong Kong.
Implications to companies: the changes that will affect your business
The new approach may increase the efficiency of the SFC in handling investigations into the irregular conduct of licensees, companies, and also individuals. The cooperation between the SFC and the licensed entities is also going to be tighter.
However, this approach may also cause the compliance cost of licensees and companies to soar. Licensees and companies may need to conduct excessive internal reviews and monitoring in order to meet the requirements of the regulators, albeit there may not be any material findings on any misconducts.
The lack of universal standards for internal reviews conducted by licensees and companies may also be problematic, as the standard of review would vary from one licensee/company to another, making it difficult for licensees and companies to fully understand how to comply with the SFC’s requirements.
The expansion of enforcement powers of the Intermediaries Division may also be seen as a misplacement of resources. In essence, the roles of the Intermediaries Division and the Enforcement Division are distinct. The “front-loaded” approach delegates more enforcement power to the Intermediaries Division, despite the fact that the Division may not have enough expertise to conduct thorough investigations and obtain material findings for imposing preliminary sanctions.
To tackle such changes, listed companies and regulated activities licensees should be prepared that the SFC may take aggressive strategies to handle any irregularities spotted even at an early stage when the Enforcement Division has not been engaged. Professionals should be engaged to conduct ‘health checks’ on the entities’ internal control on a regular basis.
What we can provide to help you
Key contact

Stephen Wong
Partner
Tel: +852 2533 2525
Email: stephenwong.office@sw-hk.com
